Certara (CERT) Projected to Announce Earnings on Thursday

Certara (NASDAQ:CERT) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Certara to post earnings of $0.0866 per share and revenue of $92.01 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The business had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. During the same period last year, the business posted $0.07 earnings per share. The business’s revenue was down 10.8% on a year-over-year basis. On average, analysts expect Certara to post $0.21 EPS for the current fiscal year and $0.28 EPS for the next fiscal year.

Certara Stock Up 1.5%

Shares of Certara stock opened at $10.87 on Wednesday. Certara has a one year low of $4.45 and a one year high of $11.88. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55. The stock’s 50-day moving average is $9.12 and its 200 day moving average is $7.31. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -24.16 and a beta of 1.30.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Weiss Ratings downgraded Certara from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. Barclays increased their price target on Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. UBS Group downgraded shares of Certara from a “buy” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research report on Wednesday, September 30th. KeyCorp raised their price objective on shares of Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Finally, TD Cowen lifted their price objective on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.18.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.